The London Biotechnology Show returns for its highly anticipated second edition, building on the remarkable success of its ...

For the first quarter of 2025, the Wasatch Micro Cap Fund—Investor Class was down -16.57% but outperformed the benchmark ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

Aquaporin A/S (CSE: AQP) ("Aquaporin" or the "Company"), an innovative water technology company dedicated to rethinking water filtration with biotechnology, today announces the Company's Q1 2025 ...

Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025α7 nicotinic ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

High levels of debt obligations have led several biotechnology and pharmaceutical companies into financial distress, ...

AstraZeneca completes acquisition of biotech company, EsoBiotec: Cambridge, UK Wednesday, May 21, 2025, 09:00 Hrs [IST] AstraZeneca announced the successful completion of the acqu ...

Scientific advancements in medicine, agriculture and environmental science play a crucial role in offering solutions to ...

Life sciences veteran Peter Fischer leads CRB's newest Europe office, near Munich. The office in Penzberg is CRB's 21st ...

Regeneron Pharmaceuticals enters into asset purchase agreement to acquire 23andMe for $256 million: Tarrytown, New York Wednesday, May 21, 2025, 13:00 Hrs [IST] Regeneron Pharmace ...

More than 7 out of 10 South Korean biotech companies are facing financial difficulties, and nearly 4 in 10 have considered ...